Turn Therapeutics Inc.

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving…